We consider our drug will replace CPAP as the number one treatment choice for Sleep Apnoea. It will also revolutionise the management of low-tone muscle disorders.

Adjunct Professor Anthony Sasse, Founder.

Welcome to Snoretox Pty Ltd.

In the laboratories of RMIT University, in Melbourne, Australia, we have invented and patented the world’s first effective and long-lasting muscle toning drug.

Our game-changing technology is based on molecules of tetanus toxin, modified to ensure they work around the tetanus vaccine.

Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of tetanus toxin to achieve the opposite effect – muscle toning.

Our Aim:

To improve the quality of life for both humans and animals with low tone muscle disorders such as:

  • Sleep apnoea and snoring
  • Cosmetic muscle toning (eyelid issues such as ectropion and ptosis, facial and chin lifting, general muscle toning)
  • Sphincter weakness (anal, oesophageal, bladder, pelvic floor)
  • Neurological (Multiple Sclerosis, Motor Neuron Disease, Myopathy)
  • Veterinary (sleep apnoea, “roaring” larynx disorders, sphincter incontinence, muscle weakness)

Our therapeutics are trademarked SnoretoxTM (for sleep apnoea) and TonetoxTM (for other applications).

Download the detailed Snoretox summary pdf here.